# Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Source: https://onco.cc/trials/nct06502977/  
OnCo record `nct06502977` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment is a phase 2 interventional study registered as NCT06502977 by Amgen, with 32 participants enrolled, started 2024-08-27 and due to reach its primary completion in 2025-03-28. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: DeLLphi-307
- Tags: ctgov-ingest
- Registry id: NCT06502977
- Phase: 2
- Setting: Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
- Sponsor: Amgen
- Enrolled: 32
- Outcomes: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1): Tarlatamab 38.7%

## Sources

- ClinicalTrials.gov NCT06502977: https://clinicaltrials.gov/study/NCT06502977

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06502977.json